Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...
Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...
Recursion Pharmaceuticals (NASDAQ: RXRX) is a relatively small player in the biotech industry. The same is true in artificial intelligence (AI), a market where it is barely on the map, given the giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results